Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents
Abstract Introduction Although the combination of venetoclax (VEN) and hypomethylating agents (HMAs) results in impressive efficacy in acute myeloid leukemia (AML), there is still a subset of patients who are refractory. We investigated the outcomes of AML patients with monocytic differentiation who...
Saved in:
| Main Authors: | Dian Jin, Jingsong He, Haoguang Chen, Wenjun Wu, Xiaoyan Han, Jing Le, Wenxiu Shu, Qianqian Yang, Shanshan Pei, Zhen Cai, Donghua He |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-07-01
|
| Series: | Cancer Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cam4.7378 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study
by: Fei Xin, et al.
Published: (2024-12-01) -
Hemophagocytic lymphohistiocytosis secondary to refractory acute myeloid leukemia resolved after second line treatment with azacitidine plus venetoclax
by: Claudio Fozza
Published: (2024-01-01) -
TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS
by: Eleonora De Bellis, et al.
Published: (2017-07-01) -
Valproic Acid Enhances Venetoclax Efficacy in Targeting Acute Myeloid Leukemia
by: Renshi Kawakatsu, et al.
Published: (2025-01-01) -
Combining azole antifungals with venetoclax plus azacitidine in patients with newly diagnosed acute myeloid leukemia
by: Xushu Zhong, et al.
Published: (2024-12-01)